Evidence map›Paper›PMID 35757692›Full record

ArticleFrontiers in immunology2022

Mahya Sadat Lajevardi, Elham Gholami, Tahereh Taheri, Hamzeh Sarvnaz, Sima Habibzadeh, Negar Seyed, Yousef Mortazavi, Sima Rafati

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Live attenuated-nonpathogenicFrontiers in microbiology · 2024
    Review
  6. Synthetic biology for combating leishmaniasis.Frontiers in microbiology · 2024
    Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mahya Sadat LajevardiDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Elham GholamiDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Tahereh TaheriDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Hamzeh SarvnazDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Sima HabibzadehDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Negar SeyedDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Yousef MortazaviDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Sima RafatiDepartment of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Pasteur Institute of Iran · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a neglected vector-borne disease caused by

Indexed as

LeishmaniaLeishmaniasis, CutaneousLeishmaniasis VaccinesParasitesPsychodidaeAnimalsMiceMice, Inbred BALB CSalivary Proteins and PeptidesVaccines, AttenuatedLeishmaniasis VaccinesSalivary Proteins and PeptidesVaccines, Attenuatedcutaneous leishmaniasisLeishmania majorLeishmania tarentolaeLeishmania tropicalive vaccinesalivary proteinssand fly

Identifiers

PMID35757692
PMCPMC9226313
OpenAlexW4281758806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.